Alnylam Announces Promotion of Pushkal Garg to Chief Research and Development Officer

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNA interference (RNAi) therapeutics company, today announced that Pushkal Garg, M.D., has been appointed Executive Vice President, Chief Research and Development Officer to oversee an integrated R&D organization. Building on the launch of AMVUTTRA ® in transthyretin amyloidosis with cardiomyopathy (ATTR-CM), Alnylam is entering a new phase of growth, and a combined R&D organization will accelerate pipeline progress by fostering earlier collaboration, faster decision-making, and more agile responses to both scientific opportunity and patient need.
'I could not be more excited for Pushkal to take the helm of the combined R&D organization, given his strategic vision, operational excellence and impressive track record building and steering an industry-leading, innovative drug development organization that has delivered a new class of medicines to the world,' said Yvonne Greenstreet, M.D., Chief Executive Officer of Alnylam. 'In recent years, we've made remarkable progress across all facets of our innovation engine, achieving numerous drug approvals and positive Phase 3 readouts, and rapidly increasing the size of our clinical pipeline. As our science has advanced, so has the need for tighter alignment across Research and Development to ensure that we continue to scale our impact and transform the lives of patients across a growing number of diseases.'
'As we begin this exciting new chapter, I am energized about what lies ahead for Alnylam R&D and for patients,' said Dr. Garg. 'I believe we are just beginning to scratch the surface of what RNAi therapeutics can do to improve human health. Our ambition is to deliver RNAi therapeutics to every major tissue in the body and thereby address many additional diseases that lack effective treatments. It's a privilege for me to have the opportunity to work with and lead an integrated R&D organization that has already validated a new class of medicines so that we can imagine the next generation of treatments, drive them from the lab to approval, and help patients live healthier lives.'
Dr. Garg joined Alnylam in 2014 to build and lead the Company's Development group. He previously held leadership roles at Bristol-Myers Squibb and Millennium Pharmaceuticals. He received a B.A. with high honors in Biochemistry from the University of California, Berkeley, and an M.D. from the University of California, San Francisco (UCSF). He completed residency training in Internal Medicine at UCSF, was a fellow in the Robert Wood Johnson Clinical Scholars Program at Johns Hopkins University, and served on the faculty of Harvard Medical School and the Brigham & Women's Hospital in Boston prior to joining the industry.
About RNAi Therapeutics
RNAi (RNA interference) is a natural cellular process of gene silencing that represents one of the most promising and rapidly advancing frontiers in biology and drug development today. Its discovery has been heralded as 'a major scientific breakthrough that happens once every decade or so,' and was recognized with the award of the 2006 Nobel Prize for Physiology or Medicine. By harnessing the natural biological process of RNAi occurring in our cells, a new class of medicines known as RNAi therapeutics is now a reality. Small interfering RNA (siRNA), the molecules that mediate RNAi and comprise Alnylam's RNAi therapeutic platform, function upstream of today's medicines by potently silencing messenger RNA (mRNA) – the genetic precursors that encode for disease-causing or disease pathway proteins – thus preventing them from being made. This is a revolutionary approach with the potential to transform the care of patients with genetic and other diseases.
About Alnylam Pharmaceuticals
Alnylam (Nasdaq: ALNY) has led the translation of RNA interference (RNAi) into a whole new class of innovative medicines with the potential to transform the lives of people afflicted with rare and prevalent diseases with unmet need. Based on Nobel Prize-winning science, RNAi therapeutics represent a powerful, clinically validated approach yielding transformative medicines. Since its founding in 2002, Alnylam has led the RNAi Revolution and continues to deliver on a bold vision to turn scientific possibility into reality. Alnylam has a deep pipeline of investigational medicines, including multiple product candidates that are in late-stage development. Alnylam is executing on its 'Alnylam P5x25' strategy to deliver transformative medicines in both rare and common diseases benefiting patients around the world through sustainable innovation and exceptional financial performance, resulting in a leading biotech profile. Alnylam is headquartered in Cambridge, MA.
Alnylam Forward-Looking Statements
This press release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. All statements other than historical statements of fact regarding Alnylam's expectations, beliefs, goals, plans or prospects including, without limitation, Alnylam's expectation that a combined R&D organization will accelerate pipeline progress; Alnylam's ability to scale its impact and transform the lives of patients across a growing number of diseases; the potential for RNAi therapeutics to improve human health; Alnylam's ability to deliver RNAi therapeutics to every major tissue in the body and to address many additional diseases that lack effective treatments; and Alnylam's ability to imagine the next generation of treatments, achieve regulatory approval for additional treatments and to help patients live healthier lives should be considered forward-looking statements. Actual results and future plans may differ materially from those indicated by these forward-looking statements as a result of various important risks, uncertainties and other factors, including, without limitation, risks and uncertainties relating to: Alnylam's ability to successfully execute on its 'Alnylam P 5 x25' strategy; Alnylam's ability to successfully demonstrate the efficacy and safety of its product candidates; the pre-clinical and clinical results for Alnylam's product candidates; actions or advice of regulatory agencies and Alnylam's ability to obtain regulatory approval for its product candidates, as well as favorable pricing and reimbursement; successfully launching, marketing and selling Alnylam's approved products globally; and any delays, interruptions or failures in the manufacture and supply of Alnylam's product candidates or its marketed products; as well as those risks more fully discussed in the 'Risk Factors' filed with Alnylam's 2024 Annual Report on Form 10-K filed with the Securities and Exchange Commission (SEC), as may be updated from time to time in Alnylam's subsequent Quarterly Reports on Form 10-Q and in its other SEC filings. In addition, any forward-looking statements represent Alnylam's views only as of today and should not be relied upon as representing its views as of any subsequent date. Alnylam explicitly disclaims any obligation, except to the extent required by law, to update any forward-looking statements.

Try Our AI Features

Explore what Daily8 AI can do for you:

Learn with AIFact CheckingText to SpeechAI Summary

Related Articles

Yahoo

25 minutes ago

• Yahoo

B. Riley Lowers Price Target on FuelCell Energy, Inc. (FCEL)

FuelCell Energy, Inc. (NASDAQ:FCEL) is among the 13 Best Hydrogen and Fuel Cell Stocks to Buy According to Analysts. Riley has maintained its Neutral rating on FuelCell Energy, Inc. (NASDAQ:FCEL) and reduced its price target from $9 to $8 in response to the company's fiscal Q2 results. An industrial setting, with a fuel cell power plant against a backdrop of smoke stacks. The company mentioned that its recent cost-cutting initiatives resulted in a slight decrease in forecasts. FuelCell has reduced its headcount by 22% and plans to reduce annualized cost by 30% in comparison to fiscal 2024. The company's move toward stricter cost controls in the face of persistent operational difficulties is reflected in these initiatives. B. Riley's updated forecast reflects cautious investor sentiment as FuelCell Energy, Inc. (NASDAQ:FCEL) works through its reorganization. FuelCell Energy, Inc. (NASDAQ:FCEL) is a fuel cell power firm and one of the best hydrogen stocks. The company creates, manufactures, sells, installs, operates, and services fuel cell products and electrolysis platforms that reduce carbon emissions and generate hydrogen. FuelCell Energy, Inc. (NASDAQ:FCEL) provides services to many industries, including commercial and hospitality, wastewater treatment, education and healthcare, data centers, and industrial. Geographically, the business is active in Europe, Canada, South Korea, and the United States. The USA and South Korea account for the majority of revenue. While we acknowledge the potential of FCEL as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock. READ NEXT: 10 High-Growth EV Stocks to Invest In and 13 Best Car Stocks to Buy in 2025. Disclosure. None. Sign in to access your portfolio

Business Wire

3 hours ago

• Business Wire

Kioxia Broadens 8th Generation BiCS FLASH™ SSD Portfolio with High-Performance Data Center NVMe™ SSDs to Maximize GPU Utilization in AI and HPC (High-performance computing) Workloads

TOKYO--(BUSINESS WIRE)-- Kioxia Corporation, a world leader in memory solutions, today announced the prototype development and demonstration of its new KIOXIA CD9P Series PCIe® 5.0 NVMe™ SSDs. These next-generation drives are the latest SSDs built with Kioxia's 8th generation BiCS FLASH™ TLC-based 3D flash memory. 8th generation BiCS FLASH™ features CBA (CMOS directly Bonded to Array) technology, a breakthrough architecture that significantly boosts power efficiency, performance, and storage density [1], while doubling the capacity available per SSD compared with the previous generation model [2]. As GPU-accelerated AI servers drive up the demands on storage infrastructure, maintaining high throughput, low latency, and consistent performance is critical -- including keeping valuable GPUs highly utilized. The KIOXIA CD9P Series is purpose-built for these next-generation environments, delivering the speed and responsiveness required by AI, machine learning and HPC (high-performance computing) workloads to ensure GPUs stay fed with data and operating at maximum efficiency. The CD9P Series leverages Kioxia's most advanced 3D flash memory to date, featuring a CBA-based architecture that reduces heat generation, enhances thermal management, and delivers greater overall value through improved performance and power metrics and total cost of ownership. KIOXIA CD9P Series drives deliver 4-corner performance improvements of up to approximately 125% in random write, 30% in random read, 20% sequential read, and 25% in sequential write speeds compared to the previous generation [2]. Furthermore, performance per watt of power consumption has improved by approximately 60% in sequential read, 45% in sequential write, 55% in random read, and 100% (2x) in random write [2]. (Applies to the 15.36 terabyte (TB) model) KIOXIA CD9P Series SSD highlights include (preliminary and subject to change): PCIe ® 5.0, NVMe™ 2.0, NVMe-MI™ 1.2c compliant Open Compute Project Datacenter NVMe™ SSD specification v2.5 support (Not all requirements) Form factors: 2.5-inch 15 mm thickness, EDSFF E3.S Read-intensive (1 DWPD) and mixed-use (3 DWPD) endurances Sequential performance (128 KiB/QD32) - 14.8 GB/s Read and 7 GB/s Write Random performance (4KiB) - 2,600 KIOPS (QD512) Read and 750 KIOPS (QD32) Write 2.5-inch capacities up to 61.44 TB and E3.S capacities up to 30.72 TB CNSA 2.0 algorithm support [3] (Prepared for the threat posed by quantum computers) KIOXIA CD9P Series SSDs are now sampling to select customers and will be showcased at HPE Discover 2025, taking place June 23-26 in Las Vegas. Notes [1] Compared to the 6th generation BiCS FLASH™ [2] Compared to the KIOXIA CD8P Series [3] The KIOXIA CD9P Series supports Leighton-Micali Signature (LMS) algorithm acknowledged by CNSA 2.0 [4] as a digital signature algorithm to prevent firmware tampering in preparation for threats to conventional cryptographic algorithms posed by quantum computers. Advanced Encryption Standard (AES-256) with a key length of 256 bits, which is the data encryption algorithm used in CD9P, is also acknowledged by CNSA 2.0. [4] CNSA2.0: Commercial National Security Algorithm Suite 2.0 *2.5-inch indicates the form factor of the SSD and not its physical size. *Read and write speed may vary depending on various factors such as host devices, software (drivers, OS etc.) and read/write conditions. *Performance is preliminary and subject to change without notice. *Definition of capacity: Kioxia Corporation defines a kilobyte (KB) as 1,000 bytes, a megabyte (MB) as 1,000,000 bytes, a gigabyte (GB) as 1,000,000,000 bytes, a terabyte (TB) as 1,000,000,000,000 bytes, and a kibibyte (KiB) is 1,024 bytes. A computer operating system, however, reports storage capacity using powers of 2 for the definition of 1GB = 2^30 bytes = 1,073,741,824 bytes and 1TB = 2^40 bytes = 1,099,511,627,776 bytes and therefore shows less storage capacity. Available storage capacity (including examples of various media files) will vary based on file size, formatting, settings, software and operating system, and/or pre-installed software applications, or media content. Actual formatted capacity may vary. *A kibibyte (KiB) means 2^10, or 1,024 bytes. *IOPS: Input Output Per Second (or the number of I/O operations per second) *NVMe and NVMe-MI are registered or unregistered trademarks of NVM Express, Inc. in the United States and other countries. *PCIe is a registered trademark of PCI-SIG. *HPE is a trademark of Hewlett Packard Enterprise Company and/or its affiliates. *Other company names, product names and service names may be trademarks of third-party companies. About Kioxia Kioxia is a world leader in memory solutions, dedicated to the development, production and sale of flash memory and solid-state drives (SSDs). In April 2017, its predecessor Toshiba Memory was spun off from Toshiba Corporation, the company that invented NAND flash memory in 1987. Kioxia is committed to uplifting the world with 'memory' by offering products, services and systems that create choice for customers and memory-based value for society. Kioxia's innovative 3D flash memory technology, BiCS FLASH™, is shaping the future of storage in high-density applications, including advanced smartphones, PCs, automotive systems, data centers and generative AI systems. Customer Inquiries: Kioxia Group Global Sales Offices *Information in this document, including product prices and specifications, content of services and contact information, is correct on the date of the announcement but is subject to change without prior notice.

Yahoo

4 hours ago

• Yahoo

Why Lyft (LYFT) is a Top Value Stock for the Long-Term

Taking full advantage of the stock market and investing with confidence are common goals for new and old investors alike. Achieving those goals is made easier with the Zacks Style Scores, a unique set of guidelines that rates stocks based on popular investing methodologies, namely value, growth, and momentum. The Style Scores can help you narrow down which stocks are better for your portfolio and which ones can beat the market over the long-term. Value investors love finding good stocks at good prices, especially before the broader market catches on to a stock's true value. Utilizing ratios like P/E, PEG, Price/Sales, and Price/Cash Flow, the Value Style Score identifies the most attractive and most discounted stocks. Lyft, based in San Francisco, CA, was founded in 2012. The company, however, made its trading debut on the Nasdaq in March 2019. Its IPO price was $72 a share. Lyft completed its IPO on Apr 2, 2019. During the process, the company sold 32,500,000 shares of Class A common stock. On Apr 9, 2019, Lyft sold 2,996,845 more shares of Class A common stock at $72 per share. LYFT sits at a Zacks Rank #2 (Buy), holds a Value Style Score of B, and has a VGM Score of A. Compared to the Internet - Services industry's P/E of 18.3X, shares of Lyft are trading at a forward P/E of 13.3X. LYFT also has a PEG Ratio of 0.6, a Price/Cash Flow ratio of 56.2X, and a Price/Sales ratio of 1X. A company's earnings performance is important for value investors as well. For fiscal 2025, seven analysts revised their earnings estimate higher in the last 60 days for LYFT, while the Zacks Consensus Estimate has increased $0.10 to $1.11 per share. LYFT also holds an average earnings surprise of 24.2%. Investors should take the time to consider LYFT for their portfolios due to its solid Zacks Ranks, notable earnings and valuation metrics, and impressive Value and VGM Style Scores. Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report Lyft, Inc. (LYFT) : Free Stock Analysis Report This article originally published on Zacks Investment Research ( Zacks Investment Research